Checkpoint Therapeutics’ (CKPT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

Checkpoint Therapeutics Stock Down 1.2 %

NASDAQ:CKPT opened at $2.43 on Monday. Checkpoint Therapeutics has a 52 week low of $1.30 and a 52 week high of $3.62. The company has a fifty day simple moving average of $2.33 and a two-hundred day simple moving average of $2.03. The company has a market cap of $86.72 million, a price-to-earnings ratio of -0.88 and a beta of 1.29.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.11. The firm had revenue of $0.04 million for the quarter. On average, analysts expect that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Insider Transactions at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total transaction of $50,450.50. Following the completion of the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at $4,053,198.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO William Garrett Gray sold 13,038 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total value of $26,858.28. Following the completion of the sale, the chief financial officer now directly owns 672,186 shares of the company’s stock, valued at approximately $1,384,703.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO James F. Oliviero III sold 24,610 shares of Checkpoint Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the transaction, the chief executive officer now directly owns 1,977,170 shares in the company, valued at approximately $4,053,198.50. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

A number of large investors have recently bought and sold shares of CKPT. XTX Topco Ltd purchased a new stake in shares of Checkpoint Therapeutics in the second quarter valued at about $34,000. Lindbrook Capital LLC acquired a new position in Checkpoint Therapeutics in the 1st quarter valued at about $62,000. 180 Wealth Advisors LLC purchased a new stake in Checkpoint Therapeutics during the 2nd quarter valued at approximately $96,000. Choreo LLC lifted its position in Checkpoint Therapeutics by 200.9% during the 1st quarter. Choreo LLC now owns 57,922 shares of the company’s stock worth $119,000 after acquiring an additional 38,672 shares during the period. Finally, PVG Asset Management Corp purchased a new position in shares of Checkpoint Therapeutics in the 2nd quarter valued at approximately $295,000. Institutional investors and hedge funds own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.